Octreotide

Octreotide is a cyclic octapeptide that mimics the biological actions of endogenous somatostatin with substantially greater potency and a much longer half-life. Native somatostatin is eliminated within 1–3 minutes; octreotide has an elimination half-life of 1.7–1.9 hours after subcutaneous administration, extending to 3.7 hours in hepatic cirrhosis.

Octreotide binds with high affinity to somatostatin receptor subtypes 2 (SSTR2) and 5 (SSTR5), and with lower affinity to SSTR3. These are Gi/o protein-coupled receptors. Receptor binding activates inhibitory Gi proteins, which suppress adenylate cyclase activity, reduce intracellular cyclic AMP, activate inwardly rectifying potassium channels, and inhibit voltage-gated calcium channels. The net result is membrane hyperpolarization and suppression of hormone secretion from neuroendocrine cells.

In acromegaly, the dominant mechanism is direct suppression of growth hormone (GH) release from somatotroph adenoma cells, with secondary reduction in hepatic insulin-like growth factor-1 (IGF-1) synthesis. Octreotide also blunts GH responses to stimuli such as exercise and hypoglycemia.

In carcinoid tumors and VIPomas, octreotide inhibits release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and substance P. This suppresses the excessive hormone secretion responsible for diarrhea, cutaneous flushing, and bronchoconstriction.

• Additional physiologic effects include inhibition of glucagon and insulin secretion, suppression of TSH response to TRH, reduction of splanchnic blood flow via decreased portal venous inflow, and blunting of the LH response to GnRH. • The antiproliferative effect observed in neuroendocrine tumors is mediated through SSTR2-dependent induction of cell cycle arrest and apoptosis, as well as indirect suppression of growth factor signaling.

The clinical evidence base for octreotide spans more than three decades and includes randomized controlled trials, large prospective cohort studies, and systematic reviews.

Acromegaly: In the pivotal Sandostatin LAR registration trials (n = 261 acromegalic patients across multiple studies), the LAR formulation achieved mean GH levels below 5 ng/mL in 83–97% of patients and below 2.5 ng/mL in 47–66%, with IGF-1 normalization in approximately 51–57%. A prospective, multicentre open-label study across 31 centers in 15 countries (n = 98 previously untreated patients, PMC1974838) reported that after 48 weeks of LAR therapy, 44% achieved GH at or below 2.5 mcg/L and 34% achieved normal IGF-1; tumor volume reduction of 20% or greater was observed in 72% of patients with macroadenomas (mean reduction 35%) and in all evaluable microadenoma patients (mean reduction 70%). A meta-analysis of first-generation SRL trials found pooled GH and IGF-1 control rates of approximately 55–56% across diverse study populations.

Neuroendocrine tumors — antiproliferative effect: The PROMID trial (NCT00171873; Rinke et al., Journal of Clinical Oncology, 2009; PMID 19704057) was the first placebo-controlled, double-blind randomized study to confirm antiproliferative activity of octreotide LAR 30 mg monthly in 85 treatment-naive patients with metastatic midgut NETs. Median time to tumor progression was 14.3 months in the octreotide arm versus 6.0 months with placebo (p = 0.000072). Overall survival (reported in the long-term follow-up, PMID 26731483) was similar between arms (median approximately 84–85 months), likely confounded by 88% of placebo patients crossing over to octreotide after progression.

Carcinoid syndrome: FDA label data from 93 carcinoid patients on Sandostatin LAR showed that daily stool frequency was reduced to approximately 2–2.5 stools per day, daily flushing episodes fell to approximately 0.5–1 per day, and urinary 5-HIAA decreased by 38–50%. A prospective long-term analysis found that over 70% of patients experienced significant improvement or resolution of diarrhea and flushing.

NETTER-1 (Phase III, NEJM 2017; PMID 28076709): In 229 patients with progressive somatostatin-receptor-positive midgut NETs, the combination of lutetium-177 dotatate plus octreotide LAR 30 mg produced a 20-month progression-free survival rate of 65.2% versus 10.8% for high-dose octreotide LAR 60 mg alone (HR 0.18; 95% CI 0.11–0.29; p less than 0.0001), establishing octreotide as the standard backbone in peptide receptor radionuclide therapy regimens.

Typical dosage: 20–30 mg (LAR formulation, IM every 4 weeks); 100–600 mcg/day in divided doses (immediate-release SC) (Every 4 weeks (LAR); two to four times daily (immediate-release)).

Immediate-release injection (subcutaneous or intravenous, Sandostatin):

Acromegaly: Begin at 50 mcg subcutaneously three times daily. Titrate to 100–500 mcg three times daily based on GH/IGF-1 response, typically measured every two weeks during titration. Most patients require 300 mcg three times daily or less; doses above 300 mcg TID rarely produce additional biochemical benefit.

Carcinoid tumors: 100–600 mcg/day in two to four divided doses subcutaneously. Mean effective maintenance dose in trials was approximately 300 mcg/day; doses up to 1,500 mcg/day have been used, though experience above 750 mcg/day is limited.

VIPomas: 200–300 mcg/day in two to four divided doses (range 150–750 mcg/day); most patients are maintained below 450 mcg/day.

Long-acting release (intramuscular, Sandostatin LAR Depot):

Patients are typically stabilized on the immediate-release formulation first. For acromegaly: Begin LAR at 20 mg IM every 4 weeks. After 3 months, titrate based on GH and IGF-1: reduce to 10 mg if GH is below 1 ng/mL and IGF-1 is normal; maintain at 20 mg if GH is 1–2.5 ng/mL and IGF-1 is normal; increase to 30 mg if GH exceeds 2.5 ng/mL or IGF-1 is elevated. For carcinoid and VIPomas: Begin at 20 mg IM every 4 weeks; may increase to 30 mg every 4 weeks if symptoms are not controlled. A bridge with short-acting octreotide is recommended for the first 2 weeks after LAR initiation until depot drug levels are established.

Special populations: Patients with severe renal failure on dialysis or hepatic cirrhosis should begin at 10 mg every 4 weeks and titrate cautiously. Elderly patients experience a 46% increase in half-life and 26% reduction in clearance; no formal dose reduction is required but monitoring is advisable.

This information is provided for educational reference only and does not constitute medical advice. Dosing must be individualized by a qualified healthcare provider based on diagnosis, response, tolerability, renal and hepatic function, and concurrent medications.

Octreotide is used in several established co-administration strategies in clinical practice.

Peptide receptor radionuclide therapy (PRRT): In the NETTER-1 trial, octreotide LAR 30 mg every 4 weeks was administered concurrently with lutetium-177 dotatate (177Lu-DOTATATE) as a radiosensitizer and tumor-targeting backbone. The FDA label for lutetium-177 dotatate (Lutathera) specifies that short-acting somatostatin analogs must be withheld at least 24 hours before each dose, but long-acting octreotide LAR can be continued. This combination is now the standard of care for progressive somatostatin-receptor-positive midgut NETs.

Everolimus (mTOR inhibitor): The RADIANT-2 trial evaluated everolimus plus octreotide LAR 30 mg versus placebo plus octreotide LAR in patients with NETs and carcinoid syndrome. The combination arm showed median PFS of 16.4 months versus 11.3 months with octreotide alone (HR 0.77), and chromogranin A response was higher in the combination arm (45.7% vs. 28.8%). This combination is employed in some patients with progressive pancreatic or carcinoid NETs.

Acromegaly add-on: When octreotide LAR alone produces partial biochemical control, it is sometimes combined with pegvisomant (a GH receptor antagonist) to address residual IGF-1 elevation, or with dopamine agonists (cabergoline) as an adjunct, though these combinations are largely based on clinical series rather than large randomized trials.

Carcinoid crisis prophylaxis: Intravenous octreotide (short-acting, typically 150–500 mcg IV bolus followed by infusion) is administered perioperatively in patients with carcinoid syndrome undergoing procedures, to prevent life-threatening hemodynamic instability (carcinoid crisis). This is standard of care in endocrine surgery practice, though supporting evidence is largely observational.

Octreotide is approved by the U.S. Food and Drug Administration for one or more clinical indications. Refer to the prescribing information for full safety and dosing details.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Gallstones and biliary sludge, diarrhea, nausea, abdominal discomfort, sinus bradycardia, hyperglycemia, hypoglycemia, hypothyroidism, steatorrhea, injection-site pain

Gastrointestinal effects are the most common adverse reactions and occur in 34–61% of acromegalic patients on the immediate-release formulation, including diarrhea (most frequent), loose stools, nausea, abdominal discomfort, and flatulence; 2.6% of patients discontinued because of GI symptoms. With Sandostatin LAR, diarrhea occurred in 35.6%, abdominal pain in 28.7%, and flatulence in 25.3% of acromegalic patients.

Biliary effects: Cholelithiasis and biliary sludge represent a major concern. In acromegalic patients receiving long-term octreotide injection, 63% developed biliary tract abnormalities (27% gallstones, 24% sludge); the cumulative incidence of stones or sludge reached 52% after 12 months. Most cases are asymptomatic; baseline and periodic ultrasound monitoring is recommended.

Glucose metabolism: Octreotide inhibits both insulin and glucagon secretion. Hyperglycemia occurred in approximately 16% and hypoglycemia in 3% of acromegalic patients in registration trials; overt diabetes mellitus may emerge with prolonged therapy. Glucose monitoring and antidiabetic dose adjustment are required, particularly in existing diabetics.

Cardiovascular: Sinus bradycardia (heart rate below 50 bpm) developed in 25% of acromegalic patients in LAR trials; cardiac conduction abnormalities in 10%. Complete atrioventricular block has been reported with IV octreotide during surgical procedures; cardiac monitoring is advised for IV administration. Additive bradycardia may occur with concurrent beta-blockers; dose adjustment may be needed.

Thyroid: TSH suppression occurs; biochemical hypothyroidism developed in 12% of patients on injectable octreotide in trials, and 4% required thyroid replacement therapy. Baseline and periodic thyroid function tests are recommended during chronic therapy.

Steatorrhea and fat malabsorption: Reversible inhibition of pancreatic enzyme and bile acid secretion may cause steatorrhea, loose stools, and fat-soluble vitamin malabsorption; depressed vitamin B12 levels have been documented and monitoring is advised. Pancreatitis has been reported in post-marketing surveillance.

Anaphylactoid reactions and injection-site reactions have been reported. Contraindication: hypersensitivity to octreotide or any excipient. No black-box warning appears on the current FDA label for octreotide injection or LAR.